Sirt1 decreased adipose inflammation by interacting with Akt2 and inhibiting mTOR/S6K1 pathway in mice

Journal of Lipid Research

Volumn 57, Issue 8, 2016, Pages 1373-1381

  Liu, Zhenjiang ^a   Gan, Lu ^a   Liu, Guannv ^a   Chen, Yizhe ^a   Wu, Tianjiao ^a   Feng, Fei ^a   Sun, Chao ^a  

^a NORTHWEST A F UNIVERSITY   (China)

Author keywords

Mammalian target of rapamycin c1; Mammalian target of rapamycin s6 kinase 1; Protein kinase B; Sirtuin type 1

Indexed keywords

COMPLEMENTARY DNA; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 6; LIPID; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE; PROTEIN KINASE B; RAPAMYCIN; RESVERATROL; SHORT HAIRPIN RNA; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; AKT2 PROTEIN, MOUSE; ANTIOBESITY AGENT; MTOR PROTEIN, MOUSE; REGULATORY ASSOCIATED PROTEIN OF MTOR; RPS6KA1 PROTEIN, MOUSE; RPTOR PROTEIN, MOUSE; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SIRT1 PROTEIN, MOUSE; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; ENVIRONMENTAL TEMPERATURE; IMMUNOPRECIPITATION; IN VITRO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WHITE ADIPOSE TISSUE; ANIMAL; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTI-OBESITY AGENTS; CELLS, CULTURED; DIET, HIGH-FAT; ENZYME ACTIVATION; INFLAMMATION; INSULIN; MALE; MICE; NIACINAMIDE; OBESITY; PROTO-ONCOGENE PROTEINS C-AKT; REGULATORY-ASSOCIATED PROTEIN OF MTOR; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; SUBCUTANEOUS FAT; TOR SERINE-THREONINE KINASES;

EID: 84980349950     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M063537     Document Type: Article

References (44)

1. Rodgers, J. T., C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman, and P. Puigserver. 2005. Nutrient control of glucose homeostasis through a complex of PGC-α and SIRT1. Nature. 434: 113-118.
2. Picard, F., M. Kurtev, N. Chung, A. Topark-Ngarm, T. Senawong, and R. M. De Oliveira. 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature. 429: 771-776.
3. Yoshizaki T., J. C. Milne, T. Imamura, S. Schenk, N. Sonoda, J. L. Babendure, J. C. Lu, J. J. Smith, M. R. Jirousek, and J. M. Olefsky. 2009. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 29: 1363-1374.
4. Hotamisligil, G. S., P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
5. Gillum, M. P., M. E. Kotas, D. M. Erio, R. P. Kursawe, and K. T. Chatterjee. 2011. Sirt1 regulates adipose tissue inflammation. Diabetes. 60: 3235-3245.
6. Guarente, L. 2006. Sirtuins as potential targets for metabolic syndrome. Nature. 444: 868-874.
7. Yoshizaki, T., S. Schenk, T. Imamura, J. L. Babendure, N. Sonoda, and E. J. Bae. 2010. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 298: E419-E428.
8. Purushotham, A., T. T. Schug, Q. Xu, S. Surapureddi, X. Guo, and X. Li. 2009. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9: 327-338.
9. Park, S. J., F. Ahmad, A. Philp, K. Baar, T. Williams, H. Luo, H. Ke, H. Rehmann, R. Taussig, and A. L. Brown. 2012. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 148: 421-433.
10. Lagouge, M., C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, and P. Elliott. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-α. Cell. 127: 1109-1122.
11. Chen, M. L., L. Yi, X. Jin, X. Y. Liang, Y. Zhou, T. Zhang, Q. Xie, X. Zhou, H. Chang, and Y. J. Fu. 2013. Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway. Autophagy. 9: 2033-2045.
12. Nwachukwu, J. C., S. Srinivasan, N. E. Bruno, A. A. Parent, T. S. Hughes, J. A. Pollock, O. Gjyshi, V. Cavett, J. Nowak, and R. D. Garcia-Ordonez. 2014. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. eLife. 3: e02057.
13. Fischer-Posovszky, P., V. Kukulus, D. Tews, T. Unterkircher, K. M. Debatin, S. Fulda, and M. Wabitsch. 2010. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am. J. Clin. Nutr. 92: 5-15.
14. Bodine, S. C., T. N. Stitt, M. Gonzalez, W. O. Kline, G. L. Stover, and R. Bauerlein. 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3: 1014-1019.
15. Liu, M., J. Bai, S. He, R. Villarreal, D. Hu, and C. Zhang. 2014. Grb10 promotes lipolysis and thermogenesis by phosphorylation-dependent feedback inhibition of mTORC1. Cell Metab. 19: 967-980.
16. Guertin, D. A., and D. M. Sabatini. 2007. Defining the role of mTOR in cancer. Cancer Cell. 12: 9-22.
17. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307: 1098-1101.
18. Ravikumar, B., C. Vacher, Z. Berger, J. E. Davies, S. Luo, and L. G. Oroz. 2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36: 585-595.
19. Tilg, H., and A. R. Moschen. 2006. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6: 772-783.
20. Han, M. S., D. Y. Jung, C. Morel, S. A. Lakhani, J. K. Kim, R. A. Flavell, and R. J. Davis. 2013. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science. 339: 218-222.
21. Jiang, H., M. Westerterp, C. Wang, Y. Zhu, and D. Ai. 2014. Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. Diabetologia. 57: 2393-2404.
22. Pang, W., Y. Wang, N. Wei, R. Xu, Y. Xiong, and P. Wang. 2013. Sirt1 inhibits akt2-mediated porcine adipogenesis potentially by direct protein-protein interaction. PLoS One. 8: e71576.
23. Busch, F., A. Mobasheri, P. Shayan, R. Stahlmann, and M. Shakibaei. 2012. Sirt-1 is required for the inhibition of apoptosis and inflammatory responses in human tenocytes. J. Biol. Chem. 287: 25770-25781.
24. Chen, M., J. Breslow, W. Li, and T. Leff. 1994. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J. Lipid Res. 35: 1918-1924.
25. Lee, M. O. 1929. Determination of the surface area of the white rat with its application to the expression of metabolic results. Am. J. Physiol. 89: 24-33.
26. Gan, L., Z. Liu, W. Cao, Z. Zhang, and C. Sun. 2015. FABP4 reversed the regulation of leptin on mitochondrial fatty acid oxidation in mice adipocytes. Sci. Rep. 5: 13588.
27. Gan, L., Z. Liu, W. Jin, Z. Zhou, and C. Sun. 2015. Foxc2 enhances proliferation and inhibits apoptosis through activating Akt/mTORC1 signaling pathway in mouse preadipocytes. J. Lipid Res. 56: 1471-1480.
28. Gan, L., J. Yan, Z. Liu, M. Feng, and C. Sun. 2015. Adiponectin prevents reduction of lipid-induced mitochondrial biogenesis via AMPK/ ACC2 pathway in chicken adipocyte. J. Cell. Biochem. 116: 1090-1100.
29. Arkan, M. C., A. L. Hevener, F. R. Greten, S. Maeda, Z. W. Li, and J. M. Long. 2005. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 11: 191-198.
30. Hotamisligil, G. S. 2006. Inflammation and metabolic disorders. Nature. 444: 860-867.
31. Baur, J. A., K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, and A. Kalra. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444: 337-342.
32. Milne, J. C., P. D. Lambert, S. Schenk, D. P. Carney, J. J. Smith, and D. J. Gagne. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 450: 712-716.
33. Timmers, S., E. Konings, L. Bilet, R. H. Houtkooper, T. van de Weijer, G. H. Goossens, J. Hoeks, S. van der Krieken, D. Ryu, and S. Kersten. 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14: 612-622.
34. Feige, J. N., M. Lagouge, C. Canto, A. Strehle, S. M. Houten, J. C. Milne, P. D. Lambert, C. Mataki, P. J. Elliott, and J. Auwerx. 2008. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 8: 347-358.
35. Kadowaki, T., K. Ueki, T. Yamauchi, and N. Kubota. 2012. SnapShot: insulin signaling pathways. Cell. 148: 624.
36. Kidd, L. B., G. A. Schabbauer, J. P. Luyendyk, T. D. Holscher, R. E. Tilley, and M. Tencati. 2008. Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J. Pharmacol. Exp. Ther. 326: 348-353.
37. Cohen, H. Y., C. Miller, K. J. Bitterman, N. R. Wall, B. Hekking, and B. Kessler. 2004. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 305: 390-392.
38. Nisoli, E., C. Tonello, A. Cardile, V. Cozzi, R. Bracale, and L. Tedesco. 2005. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 310: 314-317.
39. Lee, D. F., H. P. Kuo, C. T. Chen, J. M. Hsu, C. K. Chou, and Y. Wei. 2007. IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 130: 440-455.
40. Greten, F. R., L. Eckmann, T. F. Greten, J. M. Park, Z. W. Li, and L. J. Egan. 2004. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 118: 285-296.
41. Tremblay, F., A. Gagnon, A. Veilleux, A. Sorisky, and A. Marette. 2005. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology. 146: 1328-1337.
42. Chakrabarti, P., T. English, J. Shi, C. M. Smas, and K. V. Kandror. 2010. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes. 59: 775-781.
43. Soliman, G. A. 2011. The integral role of mTOR in lipid metabolism. Cell Cycle. 10: 861-862.
44. Shaw, R. J., and L. C. Cantley. 2006. Ras, PI3K and mTOR signaling controls tumour cell growth. Nature. 441: 424-430.